Clinical Trial

Prevent Cardiac Surgery Associated AKI Trial

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Prevent CSA-AKI (Cardiac Surgery Associated Acute Kidney Injury) trial is a double blinded randomized controlled trial, 242 patients undergoing elective cardiopulmonary bypass surgery (CPB)will either receive a placebo or daily 1200 mg of Co enzyme Q10 (CoQ10) and 1000 mg of Glutathione (GSH), the first dose will be given the day before surgery and continues while admitted up to 1 week. Blood and urine samples will be collected. Adverse events related to the study drugs will be collected.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2024-09-29.
Trial Details
NCT Number NCT06620523
Lead Sponsor George Washington University
Conditions Renal Failure, Coronary Artery Disease, Surgery, Surgery-Complications
Enrollment 242 participants
Start Date 2024-07-18
Primary Completion 2027-06-17 (estimated)
Study Completion 2028-06-17 (estimated)
Updated on ClinicalTrials.gov 2025-10-08